Chemical Structure
Inhibitor
1320 Citations
Ruxolitinib
BT-0018
Ruxolitinib is a selective JAK1 and JAK2 inhibitor approved for myelofibrosis, polycythemia vera, and graft-versus-host disease.
Biological Activity
Blocks JAK1/2-mediated STAT signaling, reducing cytokine-driven inflammation and myeloproliferation.
Product Specifications
CAS Number941678-49-5
Molecular FormulaC17H18N6
Molecular Weight306.37 g/mol
TargetJAK1/JAK2
PathwayJAK/STAT Signaling
Disease AreaCancer, Immunology
IC50/EC50/KdIC50: 3.3 nM (JAK1), 2.8 nM (JAK2)
Purity>99%
SolubilityDMSO: ≥50 mg/mL
Storage-20°C
SpeciesHuman
Available Sizes
| Size | Price | |
|---|---|---|
| 10 mg | $45.00 | |
| 50 mg | $165.00 |